PSMA Theranostics: Current Status and Future Directions.

PSMA Theranostics: Current Status and Future Directions. Mol Imaging. 2018 Jan-Dec;17:1536012118776068 Authors: Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H Abstract Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed. PMID: 29873291 [PubMed - in process]
Source: Molecular Imaging - Category: Radiology Tags: Mol Imaging Source Type: research